XNCR Xencor Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: XNCR

Price (delayed)

$37.09

Market cap

$2.78B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.57

Enterprise value

$2.88B

?
Relative Growth: Rel. Growth: 64
Relative Strength: Rel. Strength: 99
Relative Valuation: Rel. Valuation: 6
Relative Profitability: Rel. Profitability: 40

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in ...

Highlights
XNCR's revenue has surged by 91% since the previous quarter and by 34% year-on-year
The gross profit has soared by 91% from the previous quarter and by 34% YoY
XNCR's equity is up by 11% since the previous quarter but it is down by 10% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.xencor.com
Peers: AMGN MGNX MRK ABBV

Key stats

What are the main financial stats of XNCR

XNCR stock price

How has the Xencor stock price performed over time
Intraday
-2.73%
1 week
3.75%
1 month
57.7%
1 year
165.12%
YTD
142.26%
QTD
48.66%

Financial performance

How have Xencor's revenue and profit performed over time
Revenue
$200.49M
Gross profit
$200.49M
Operating income
-$145.69M
Net income
-$117.86M
Gross margin
100%
Net margin
-58.8%
XNCR's revenue has surged by 91% since the previous quarter and by 34% year-on-year
The gross profit has soared by 91% from the previous quarter and by 34% YoY
XNCR's operating margin has surged by 65% since the previous quarter and by 20% year-on-year
Xencor's net margin has surged by 62% QoQ and by 32% YoY

Price vs fundamentals

How does XNCR's price correlate with its fundamentals

Growth

What is Xencor's growth rate over time

Valuation

What is Xencor stock price valuation
XNCR P/E details
P/E
N/A
P/B
4.92
P/S
14.1
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
14.37
The EPS has increased by 28% QoQ and by 9% YoY
XNCR's P/B is 134% above its 5-year quarterly average of 2.1 and 114% above its last 4 quarters average of 2.3
XNCR's equity is up by 11% since the previous quarter but it is down by 10% year-on-year
XNCR's revenue has surged by 91% since the previous quarter and by 34% year-on-year
XNCR's P/S is 60% above its 5-year quarterly average of 8.8 and 42% above its last 4 quarters average of 9.9

Efficiency

How efficient is Xencor business performance
The ROS has soared by 64% QoQ and by 28% YoY
The ROIC has grown by 28% from the previous quarter but it has contracted by 15% YoY
XNCR's ROE is up by 26% from the previous quarter but it is down by 4.4% YoY
The ROA has grown by 25% from the previous quarter but it has contracted by 4.8% YoY

Dividends

What is XNCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for XNCR.

Financial health

How did Xencor financials performed over time
XNCR's total liabilities is down by 14% year-on-year and by 5% since the previous quarter
The total assets has declined by 11% year-on-year but it has increased by 6% since the previous quarter
Xencor's debt is 71% lower than its equity
Xencor's debt has decreased by 21% YoY and by 6% QoQ
The debt to equity has decreased by 15% from the previous quarter and by 9% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.